Medical Monitoring
Our Medical Monitoring services include globally accessible medical experts, seamless sponsor collaboration, and data-driven management that ensures patient safety.
Medical Monitoring
for Safety, Quality,
and Compliance
Our Medical Monitoring team delivers expert oversight to ensure patient safety, protocol compliance, and high-quality data across all phases of clinical development. Through ongoing data review and close collaboration with investigators and investigative sites, we deliver timely medical insights that enhance trial integrity and support the development of innovative therapies.
What We Offer
Our medical monitoring services include:
Global medical monitor coverage available 24/7/365
- Expert protocol and medical input from study start-up through close-out
- Patient eligibility and enrollment review
- Real-time medical guidance for site staff
- Collaborative development of Medical Monitoring Plans and Safety Monitoring Plans
- Ongoing safety data monitoring and medical review
- Strategic participation in Safety Review Committees (SRCs) and Data Monitoring Committees (DMCs)
- Thorough, timely SAE review and assessment
- Expert guidance on protocol deviations, clinical exception handling, and patient eligibility adjudication
- Medical and clinical development input for clinical development planning, regulatory strategy, and submissions
Why Choose Everest for Your
Medical Monitoring?
Always-On Support
Our Medical Monitors are available 24/7/365 to support urgent site needs, including protocol clarifications, patient eligibility assessments, and emerging safety concerns—ensuring patient care and study progress are never delayed.
Therapeutic and Operational Expertise
Data-Driven Oversight
Transparent Collaboration
Team Leadership
Henry J. Castro, MD
Dr. Castro brings over 25 years of distinguished experience in global clinical development across oncology, immunology, and hematology. He has held senior leadership positions at leading pharmaceutical and biotechnology companies, where he successfully led the design, execution, and oversight of complex multinational trials across all phases of development. His expertise spans immuno-oncology, targeted therapies, monoclonal antibodies, and small-molecule programs in both solid tumors and hematologic malignancies. Dr. Castro has played a central role in advancing investigational agents through translational research, early-phase development, and pivotal studies that have supported regulatory approvals worldwide.